16 February 2022 in Cancer Immunology Research
T-cell receptors (TCR) recognize intracellular and extracellular cancer antigens, allowing T cells to target many tumor antigens. To sustain proliferation and persistence, T cells require not only signaling through the TCR (signal 1), but also costimulatory (signal 2) and cytokine (signal 3) signaling. Because most cancer cells lack costimulatory molecules, TCR engagement at the tumor site results in incomplete T-cell activation and transient antitumor effects. To overcome this lack of signal 2, we genetically modified tumor-specific T cells with a costimulatory chimeric antigen receptor (CoCAR). Like classical CARs, CoCARs combine the antigen-binding domain of an antibody with costimulatory endodomains to trigger T-cell proliferation, but CoCARs lack the cytotoxic CD3ζ chain to avoid toxicity to normal tissues. We first tested a CD19-targeting CoCAR in combination with an HLA-A*02:01-restricted, survivin-specific transgenic TCR (sTCR) in serial cocultures with leukemia cells coexpressing the cognate peptide–HLA complex (signal 1) and CD19 (signal 2). The CoCAR enabled sTCR+ T cells to kill tumors over a median of four additional tumor challenges. CoCAR activity depended on CD19 but was maintained in tumors with heterogeneous CD19 expression. In a murine tumor model, sTCR+CoCAR+ T cells improved tumor control and prolonged survival compared with sTCR+ T cells. We further evaluated the CoCAR in Epstein–Barr virus–specific T cells (EBVST). CoCAR-expressing EBVSTs expanded more rapidly than nontransduced EBVSTs and delayed tumor progression in an EBV+ murine lymphoma model. Overall, we demonstrated that the CoCAR can increase the activity of T cells expressing both native and transgenic TCRs and enhance antitumor responses.
1 October 2026 in Cancer Research
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in more than 90% of pancreatic ductal adenocarcinomas (PDAC). Despite recent advances in targeting oncogenic KRAS, tumors eventually acquire resistance. A more comprehensive understanding of the mechanisms connecting KRAS signaling to tumor progression could facilitate the development of effective therapies to improve the treatment of KRAS-driven malignancies. In this study, we dissected how oncogenic KRAS reprograms posttranscriptional regulation in PDAC. Oncogenic KRAS altered Argonaute 2 (AGO2) phosphorylation at tyrosine 393, expanded the microRNA (miRNA)–mRNA interaction network, and impaired both mRNA destabilization and translational repression. Mapping endogenous miRNA–mRNA interactions using AGO2 chimeric enhanced cross-linking and immunoprecipitation (eCLIP) combined with genome-wide measurements of mRNA stability and translational efficiency (TE). Using thiol (SH)-linked alkylation for the metabolic sequencing of RNA and Ribo-eCLIP revealed that miRNA targets in KRAS-mutant cells exhibited increased stability and TE, even when cognate miRNA levels were unchanged. The rewiring enriched protumorigenic transcripts involved in GTPase signaling, autophagy, and metabolism, and it was accompanied by the assembly of enlarged, static processing bodies in cell lines, mouse models, and patient tumors, an effect that could be reversed by inhibiting oncogenic KRAS. Expression of a phospho-mimetic AGO2 Y393E reproduced the effects of oncogenic KRAS, whereas a phospho-deficient AGO2 Y393A blocked them. These findings identify a mechanistically distinct posttranscriptional effector arm of KRAS signaling, link AGO2 Y393 phosphorylation to both silencing dysfunction and condensate remodeling, and reveal opportunities to target RNA regulation in PDAC. Significance: Multiomic approaches reveal that oncogenic KRAS disrupts miRNA pathway and P-body dynamics through AGO2 phosphorylation, identifying an underappreciated effector arm of KRAS as a potential therapeutic target in pancreatic cancer.